TOMI's Q2 Revenue Surges 124%, Open Orders Exceed Full-Year 2025 Target
Event summary
- Q2 2026 revenue hit $2.3M, up 124% YoY, with open orders of $6.2M surpassing full-year 2025 revenue.
- Mobile Capital Equipment revenue surged 186% to $777K, while BIT Solution revenue grew 35% to $304K.
- SteraMist iHP systems saw expanded adoption in healthcare, life sciences, and emergency response sectors.
- New NV+ system sold to a major Minnesota healthcare facility, with delivery scheduled for Q3.
- Added three new distributors covering the U.S., South Africa, Argentina, and additional South American territories.
The big picture
TOMI's Q2 results highlight the accelerating adoption of its high-margin disinfection solutions, particularly in healthcare and life sciences. The company's strategic focus on recurring revenue streams through consumables and services aligns with broader industry trends toward automated, scalable biosecurity measures. With open orders already surpassing full-year 2025 revenue, TOMI is positioning itself as a key player in the rapidly growing disinfection market.
What we're watching
- Revenue Sustainability
- Whether TOMI can maintain its razor-and-blade model's momentum amid heightened demand for disinfection solutions.
- Market Expansion
- The pace at which TOMI integrates new distributors and expands into emerging markets like South Africa and Argentina.
- Automation Strategy
- How the custom engineering contract with a prominent American healthcare company evolves into larger automation projects.